Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2608 | Non-interventional study Wiki | 1.00 |
| drug3105 | Promotion of flour Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D006402 | Hematologic Diseases NIH | 0.71 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001871 | Abnormality of blood and blood-forming tissues HPO | 0.71 |
Navigate: Correlations HPO
There is one clinical trial.
Multiple observational studies show an association between fetal and post-natal aflatoxin exposure and reduced linear growth. However, the effects of confounding factors such as socio-economic status, food insecurity and nutrient deficiencies due to monotonous diets have not been ruled out. This trial will quantify the causal role of infant aflatoxin ingestion on post-natal growth by performing a cluster randomized trial in children 6-18 months of age in the Dodoma Region of Tanzania. All health facilities in one district in Dodoma will be randomized to the control or intervention arm. Infants will be recruited into the study over one year to account for seasonal variation in AF exposure. Both arms will receive infant and young child feeding education, a thermos flask and plastic measuring scoops. The intervention arm will receive a low-aflatoxin pre-blended porridge flour containing maize and groundnut (ratio 4:1 respectively) and low-aflatoxin groundnut flour, whereas in the control arm the same porridge mix will be promoted through education, but acquired by the household. The primary outcome is length-for-age Z-score at 18 months.
Description: Length for age Z score
Measure: Linear growth Time: 18 monthsDescription: Length for age Z score
Measure: Linear growth Time: 12 monthsDescription: Prevalence of stunting (<-2 LAZ)
Measure: Prevalence of stunting Time: 12 and 18 monthsDescription: Weight for age Z score
Measure: Ponderal growth Time: 12 and 18 monthsDescription: Prevalence of underweight (<-2 WAZ)
Measure: Prevalence of underweight Time: 12 and 18 monthsDescription: Concentration of aflatoxin M1 (AFM1) urinary biomarker
Measure: Concentration of urinary biomarker Time: 9, 12, 15, 18 monthsDescription: Concentration of AF blood biomarker AF-alb
Measure: Concentration of AF blood biomarker Time: 12 and 18 monthsDescription: Middle-upper-arm circumference Z score
Measure: Middle-upper-arm circumference (MUAC) Time: 12 and 18 months in full sample; 9, 12, 15, 18 months in sub-samplesDescription: Head-circumference-for-age Z score
Measure: Head circumference Time: 12 and 18 months in full sample; 9, 12, 15, 18 months in sub-samplesAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports